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Abstract: Cilengitide, a cyclic RGD pentapeptide, is currently in clinical phase III for treatment of glioblastomas and in phase II for  
several other tumors. This drug is the first anti-angiogenic small molecule targeting the integrins v3, v5 and 51. It was developed 
by us in the early 90s by a novel procedure, the spatial screening. This strategy resulted in c(RGDfV), the first superactive v3 inhibitor 
(100 to 1000 times increased activity over the linear reference peptides), which in addition exhibited high selectivity against the platelet 
receptor IIb3. This cyclic peptide was later modified by N-methylation of one peptide bond to yield an even greater antagonistic  
activity in c(RGDf(NMe)V). This peptide was then dubbed Cilengitide and is currently developed as drug by the company Merck-Serono 
(Germany).  
This article describes the chemical development of Cilengitide, the biochemical background of its activity and a short review about the 
present clinical trials. The positive anti-angiogenic effects in cancer treatment can be further increased by combination with “classical” 
anti-cancer therapies. Several clinical trials in this direction are under investigation. 
Keywords: RGD peptides, integrin antagonists, glioblastoma, N-methylation, v3, conformational restriction, cyclization.  
INTRODUCTION 
  Integrins are heterodimeric receptors that are important for cell-
cell and cell-extracellular matrix (ECM) interactions and are com-
posed of one  and one -subunit [1, 2]. These cell adhesion mole-
cules act as transmembrane linkers between their extracellular 
ligands and the cytoskeleton, and modulate various signaling path-
ways essential in the biological functions of most cells. Integrins play 
a crucial role in processes such as cell migration, differentiation, 
and survival during embryogenesis, angiogenesis, wound healing, 
immune and non-immune defense mechanisms, hemostasis and 
oncogenic transformation [1]. The fact that many integrins are also 
linked with pathological conditions has converted them into very 
promising therapeutic targets [3]. In particular, integrins v3, 
v5 and 51 are involved in angiogenesis and metastasis of solid 
tumors, being excellent candidates for cancer therapy [4-7].  
  There are a number of different integrin subtypes which recog-
nize and bind to the tripeptide sequence RGD (arginine, glycine, 
aspartic acid), which represents the most prominent recognition 
motif involved in cell adhesion. For example, the pro-angiogenic 
v3 integrin binds various RGD-containing proteins, including 
fibronectin (Fn), fibrinogen (Fg), vitronectin (Vn) and osteopontin 
[8]. It is therefore not surprising that this integrin has been targeted 
for cancer therapy and that RGD-containing peptides and pepti-
domimetics have been designed and synthesized aiming to selec-
tively inhibit this receptor [9, 10].  
  One classical strategy used in drug design is based on the 
knowledge about the structure of the receptor-binding pocket,   
preferably in complex with the natural ligand. However, this strategy, 
the so-called “rational structure-based design”, could not be applied 
in the field of integrin ligands since the first structures of integrin’s 
extracellular head groups were not described until 2001 for v3 
[11] (one year later, in 2002 the structure of this integrin in complex 
with Cilengitide was also reported [12]) and 2004 for IIb3 [13]. 
Therefore, initial efforts in this field focused on a “ligand-oriented 
design”, which concentrated on optimizing RGD peptides by means 
of different chemical approaches in order to establish structure-
activity relationships and identify suitable ligands. 
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  We focused our interest in finding ligands for v3 and based 
our approach on three chemical strategies pioneered in our group: 
1) Reduction of the conformational space by cyclization; 2) Spatial 
screening of cyclic peptides; and 3) N-Methyl scan. 
  The combination of these strategies lead to the discovery of the 
cyclic peptide c(RGDf(NMe)V) in 1995. This peptide showed sub-
nanomolar antagonistic activity for the v3 receptor, nanomolar 
affinities for the closely related integrins v5 and 51, and high 
selectivity towards the platelet receptor IIb3. The peptide was 
patented together with Merck in 1997 (patent application submitted 
in 15.9.1995, opened in 20.3.1997) [14] and first presented with 
Merck’s agreement at the European Peptide Symposium in Edin-
burgh (September 1996) [15]. The synthesis and activity of this 
molecule was finally published in 1999 [16]. This peptide is now 
developed by Merck-Serono, (Darmstadt, Germany) under the 
name "Cilengitide" and has recently entered Phase III clinical trials 
for treating glioblastoma [17]. 
  The aim of this review is to describe the chemical development 
of Cilengitide in our laboratory, the biochemical background for its 
biological activity and to give a comprehensive summary of the 
clinical trials performed so far. 
1. DISCOVERY OF CILENGITIDE: DESIGN AND SYN-
THESIS 
1.1. The RGD-Binding Motif 
  Pioneering studies by Ruoslahti and Pierschbacher in the early 
1980s revealed the RGD motif as the cell attachment site within the 
Fn module and its crucial role in the interaction of Fn with its cell 
surface receptor [18-21]. These studies initially described the 
tetrapeptide sequence Arg-Gly-Asp-Ser (RGDS) as the minimal 
binding site of Fn [19], but shortly after it was demonstrated that 
the serine residue can be replaced by other amino acids without 
significant loss of biological function, whereas arginine, glycine 
and aspartic acid are totally essential for the activity [20].
  
  Subsequently the RGD motif was found in other ECM proteins 
capable of binding to the integrin receptors (the term integrin was 
introduced by Hynes and coworkers in 1986 [22]) such as Vn, os-
teopontin, collagens, von Willebrand factor, Fg, thrombospondin 
and laminin [23-26]. Together with these findings, it was observed 
that although many integrins recognize the RGD motif, they are 
also able to discriminate among distinct natural ligands (ECM pro-
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presence of distinct amino acids flanking the RGD motif certainly 
contributes to receptor selectivity, this it is not enough to explain 
this behavior. To answer this question, it was postulated that in-
tegrin receptors are able to recognize distinct conformations of 
RGD sequences, which are maintained by the protein (secondary 
and tertiary) structure. 
  The concept of conformation-dependent recognition was sup-
ported by early studies showing that short peptides with the same 
sequence, displayed different conformations when inserted into 
unrelated proteins, and were in turn recognized by unique antibodies 
[28]. In this regard, the integration of a recognition motif into a 
cyclic peptide is a feasible way to restrict the conformational space 
of the amino acid sequence, and was demonstrated to show an   
impact on binding affinity and receptor specificity [29]. This   
concept, discussed by us already more than a quarter of a century 
ago, will be detailed in the next section. 
1.2. Restriction of Conformation by Cyclization and Spatial 
Screening 
  Linear peptides possess an enormous number of conformations 
in solution. This flexibility does not necessarily mean absence of 
biological activity for these molecules, but it is often related to poor 
selectivity. A useful way to reduce the conformational space of 
linear peptides is cyclization [29, 30]. The restriction in a mole-
cule’s conformational freedom may have positive effects in terms 
of binding affinity and selectivity to a receptor, provided that the 
biologically active conformation is allowed in the restrained con-
formational space (matched case). On the other hand, when the 
peptide is not able to adopt the bioactive conformation (mismatched 
case), the activity is considerably reduced or totally lost. The gain 
in biological activity for the matched situation is explained by the 
decrease in conformational entropy that is lost upon binding to the 
receptor, and by the pre-induced strain toward adoption of the 
bound conformation. 
  In this sense, a “promiscuous” behavior is expected for linear 
RGD-containing peptides in binding different integrin receptors, 
whereas constrained analogues may exhibit improved activity and 
selectivity profiles. This concept was proved by a disulfide cyclized 
synthetic RGD-peptide, which showed an improved inhibition of 
Vn-mediated adhesion and no inhibitory activity for Fn adhesion, 
compared to the unselective stem linear peptide [31]. It was also 
reported that reduction of disulfide bridges in several snake venom 
RGD-containing peptides, the disintegrins, significantly decreased 
their platelet aggregation inhibitory activity [32]. Although these 
studies demonstrated the importance of a restricted conformation, 
they did not give insights on the preferred conformations required 
for these peptides in order to bind to one integrin receptor or an-
other.  
  To investigate if and to what extend the spatial orientation of 
the crucial side chains is involved in activity and specificity of the 
ligands, we explored the conformational space of cyclic pentapep-
tides and hexapeptides containing the RGD sequence [33, 34].   
Cyclic pentapeptides containing one D- and four L-amino acids 
prefer a conformation with a II’ turn, in which the D-residue is 
located at the i+1 position. A loop on the other site of the cycle 
often involves a  turn. Therefore, the substitution of each L-amino 
acid by a D-amino acid will force the adoption of a II’ turn at  
different sites of the peptide, allowing the study of various   
conformations without modifying the chemical nature of the side 
chains (Fig. 1A). This concept was first described in 1986 for   
thymopoietin cyclic pentapeptides analogues [35] and later named 
“spatial screening” [36, 37]. 
  Based on this approach we synthesized a series of cyclic pen-
tapeptides with the sequence RGDFV (F and V are naturally occur-
ring amino acids next to the RGD sequence in Vn and Fg ECM 
proteins and indeed showed to be important for the biological activ-
ity in an earlier study) [38] and studied the effect on the conforma-
tion and the biological activity caused by a single D-amino acid 
substitution (Fig. 1B) [33]. As shown in Table 1, the peptide con-
taining a D-Phe,  c(RGDfV), showed an increased inhibition of 
A375 cell adhesion to laminin P1 (20-fold) and to Vn (100-fold) 
when compared to the control linear peptide GRGDS [20]. The use 
of D-Val exhibited also improved inhibitory activity but only for the 
laminin P1 substrate. On the contrary, the insertion of D-Asp or D-
Arg had a detrimental effect on activity. The low activity displayed 
by RGDFv confirmed that the increase in activity for some peptides 
was due to the spatial orientation of the side chains rather than the 
presence of a D-residue. Both A375 and HBL-100 cell lines express 
the v3 integrin, thus inhibition of their binding to Vn indicated 
an antagonistic effect of the cyclic peptides towards this receptor. 
Interestingly,  c(RGDfV) failed to reproduce the same inhibitory 
effect on IIb3 binding to Fg, demonstrating that the high activity 
obtained for Vn and laminin P1 substrates was specific for the re-
ceptor(s) recognizing these substrates (i.e. v3 and probably 
v5).  
  The conformations of c(RGDfV) and c(RGDFv) were investi-
gated by NMR spectroscopy combined with molecular dynamic 
(MD) simulations. Both peptides showed an all-trans conformation 
of all peptide bonds and the expected II’ and  turns, with the D-
residue at the i+1 position (Fig. 2). The main difference was the 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). (A) Spatial screening of cyclic pentapeptides. The D-amino acid (represented with lower case letters and black dots) tends to occupy the i+1 position 
in the II’ turn. Therefore different conformations of a bioactive sequence (e.g. ABCDE) can be analyzed without changing the chemical entity of the side 
chains. (B) Spatial screening of RGDFV cyclic pentapeptides. The lead sequence was fixed in different conformations by variation of the chirality of selected 
residues. 
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position of the RGD motif relative to the cycle turns. In c(RGDfV), 
the RGD motif forms a tight  turn with Gly in the central position. 
The Arg and Asp side chains are oriented almost parallel to one 
another on the same side of the ring. In contrast, in c(RGDFv) the 
Arg and Asp side chains point in opposite directions, keeping the 
guanidino and carboxy functional groups separated by a larger dis-
tance. Comparing these observations with the biological data (Table 
1) we hypothesized that c(RGDFv) exhibited the bioactive confor-
mation for the laminin P1 receptor, whereas the distinct conforma-
tion of c(RGDfV) would be related to the receptor-bound confor-
mation of the Vn receptor. MD simulations further showed that the 
D-Phe peptide is able to adopt the D-Val peptide’s structure via a 
Ii turn intermediate. However, the opposite conformational transi-
tion is not observed for the D-Val peptide, explaining its low activity 
for Vn and thus selectivity [39]. Concerning the other inactive   
peptides, the shifts in the position of the RGD sequence within the 
II’ turns for c(rGDFV) and c(RGdFV) would explain the poor 
activity of these molecules. The low activity of the cyclic D-Arg 
analogue was of particular interest, since the substitution of L-Arg 
by D-Arg in the linear reference peptide GRGDSP did not represent 
a significant loss of inhibitory activity of cell adhesion to Vn or Fn 
[31]. Therefore, the decrease in biological potency observed for 
c(rGDFV) was a pure conformational effect on biological activity. 
  In addition to these studies, a similar spatial screening was per-
formed for cyclic hexapeptides of the sequence c(RGDFVA) [33]. 
Conformational analysis of c(RGDfVA) revealed a II’ turn with D-
Phe at the i+1 position, but a II turn (Arg i+1, Gly i+2) instead of 
the  turn. This peptide had a 3 to 5-fold lower inhibitory activity 
for laminin adhesion when compared to the linear GRGDS, demon-
strating that a stretched conformation for cyclic RGD peptides was 
detrimental for v3-binding.  
  Further studies in this direction were pursued by synthesizing 
libraries of cyclic penta- and hexapeptides where conformational 
control was introduced by a D-residue and/or proline (turn-inducing 
amino acids). Detailed conformational analysis of these peptides 
and their correlation with adhesion inhibitory capacity, allowed a 
comprehensive description of structure-activity relationships for 
RGD-peptides binding to integrin receptors [34, 40]. It was cor-
roborated that selectivity of integrin binding peptides strongly de-
pends on the conformation they adopt. For instance, in the 
c(RGDfV) favored conformation, the RGD motif forms a kink 
around Gly. This conformation seems to be optimal for v3 bind-
ing and selective towards IIb3, since c(RGDfV) fails to inhibit 
the binding of this integrin with Fg. On the other hand, some cyclic 
hexapeptides with no affinity for v3 proved to be highly active 
inhibitors of the IIb3-mediated platelet aggregation [40]. A 
closer look on the structural data reveals that IIb3 has a wider 
RGD binding site (the distance between the C atoms of Arg and 
Asp in cyclic hexapeptides is in the range of 0.75-0.85 nm) com-
pared to a narrower binding site in integrins v3 or 51, in 
which cyclic pentapeptides would be better accommodated (C 
distances between Arg and Asp below 0.67 nm) [40, 41].  
  The above mentioned studies described the first example of   
a highly active and selective RGD-peptide and established the 
Table 1.  Inhibitory Capacity (IC50) of RGD-Containing Peptides for Cell Adhesion on Vn or Laminin Fragment P1 
IC50 (M) A375 Adhesion  IC50 (M) HBL-100 Adhesion  Peptide 
P1 Vn P1  Vn 
c(rGDFV) 114  >120  25  >120 
c(RGdFV) >120  >120  20  >120 
c(RGDfV)  1.0 0.2 0.1  0.1 
c(RGDFv) 1.9  20  0.9  30 
RGDFv  29 82 42  >170 
GRGDS 18  15  5  14 
For clarity only the more representative peptides and cell lines from the initial study are shown [33]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Chemical structure of the cyclic pentapeptides c(RGDfV) (left) and c(RGDFv) (right). Dashed lines represent essential hydrogen bonds required to 
stabilize the II’ and  turns. 
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structural basis to discriminate between different integrin subtypes 
(Fig. 3).  
  The antagonistic activity of the lead structure c(RGDfV) for 
v3 and its selectivity against IIb3 was also evaluated in a se-
ries of studies using the isolated integrin receptors [42]. As shown 
in Table 2, the cyclic peptide has more than two orders of magni-
tude higher potency inhibiting Vn binding to the isolated receptor 
than the linear peptide. In addition, it shows 350 times lower affinity 
for the platelet receptor, confirming its selectivity. Antagonistic 
properties for this peptide towards v3 were further investigated 
in vivo, where a single injection of c(RGDfV) disrupted tumor-
induced angiogenesis in a chick chorioallantoic membrane (CAM) 
model [43].  
  Further structure-activity relationship studies of c(RGDfV) also 
explored substitutions at positions 4 (D-Phe) and 5 (Val). Interest-
ingly, the presence of D-Phe and the proton of the amide bond be-
tween residues 3 and 4 (Asp and D-Phe) are essential for the activ-
ity. In contrast, the amino acid in position 5 has no effect on the 
biological activity [42]. This finding was of great value for the de-
sign of integrin ligands for a number of biomedical applications. 
E.g., replacement of valine by lysine or glutamic acid retains the 
integrin binding activity of the peptide providing a new functional 
group that can be further functionalized. For instance, the cyclic 
peptide c(RGDfK) has been widely used for coating of biomaterials 
to enhance cell adhesion or as imaging agent for tumor therapy. 
However, it is not the purpose of this review to focus on these ap-
plications, which have been carefully reviewed elsewhere [10, 44-46]. 
  These findings served to propose a receptor model for optimal 
binding with the v3 integrin (Fig. 4). This model highlights the 
main pharmacophoric features of c(RGDfV) for the interaction with 
the v3 receptor [41, 42].  
  The lead structure c(RGDfV) was subjected to a number of 
modifications such as the substitution of peptide bonds with 
thioamides [47] or their reduction [48], the incorporation of turn 
mimetics [49], the use of sugar amino acids [50] and the synthesis 
of retro-inverso analogues [51]. Together with these strategies the 
design and synthesis of totally non peptidic antagonists was also 
approached [9, 52]. However, the most important structural modifi-
cation turned out to be the incorporation of N-methyl amino acids 
into the peptide sequence [16]. This approach led to the discovery 
of Cilengitide, the first anti-angiogenic drug targeting integrins.  
1.3. N-Methyl Scan of the Lead Structure c(RGDfV) 
 N -Methylation of peptide bonds has proven to be a powerful 
technique for medicinal chemists to increase the potential of pep-
tides as drugs [53]. N-Methylation is currently used to improve the 
biological activity and selectivity profile of peptides [54] and also 
to overcome their pharmacokinetic limitations i.e. increasing their 
metabolic stability and bioavailability [55, 56]. This strategy is also 
a valuable tool to explore the bioactive conformation of biologically 
relevant peptides, since the introduction of N-methyl groups   
promotes conformational constraints that may enhance the   
population of single conformers essential for the biological activity 
[57, 58]. 
Table 2.  Biological Activity (IC50) of the v3-Selective Peptide c(RGDfV) Compared to Control Linear Peptide GRGDSPK in Inhibiting the 
Binding of Vn and Fg to Isolated Integrins v3 and IIb3 Respectively 
Peptide IC50 (M) v3 IC50 (M) IIb3 Selectivity  IIb3/v3 
GRGDSPK  1.2 ± 0.27  5.4 ± 2.0  4.5 
c(RGDfV)  0.0049 ± 0.0001  1.7 ± 0.38  347 
The selectivity for these receptors is expressed as the ratio between the IC50 values for each integrin subtype [42]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Starting from a linear, conformationally flexible and nonselective peptide, conformational restriction by cyclization and spatial screening leads to 
rigid and selective structures. The distance between Arg and Asp side chains is represented as d. This distance is smaller when the RGD motif adopts a kinked 
conformation. Adapted from [10]. 
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  Most of these unique properties were already known in the 90s. 
N-Methylation was in particular used for conformational studies 
[59, 60], and to improve the peptide’s pharmacokinetic properties 
[61] and receptor selectivity [62, 63]. In an interesting study,   
DeGrado and coworkers showed that N-methylation of the Arg 
residue in a class of RGD cyclic peptides improved their antagonistic 
activity for IIb3 due to conformational constraints in the   
peptide’s structure [64]. In a further study, they also proved how the 
exchange of an N-methylated D,L-configurated dipeptide motif by a 
L,L-dipeptide unit in a cyclic RGD peptide, resulted in a change of 
selectivity from an IIb3-selective ligand to an v3-selective 
peptide [65, 66]. This shift in selectivity is based on the distinct 
distances between the C atoms of Arg and Asp residues, which  
are much smaller for the ligands selective for v3. These results 
supported our previous hypothesis [40], which were finally   
confirmed through X-ray structure analysis of the IIb3 receptor 
[13] (see section 2.1). 
  These findings together with the positive effects in activity and 
selectivity described for the N-methylation of other bioactive pep-
tides, inspired us to perform an N-methyl scan of the lead peptide 
structure c(RGDfV) [16]. The resulting five N-methylated peptides 
are shown in Fig. (5).  
  The ability of these analogues to inhibit the binding of Vn and 
Fg to immobilized v3 and IIb3 receptors was compared with 
the original cyclic peptide c(RGDfV) and the linear control 
GRGDSPK (Table 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). The tripeptide sequence Arg-Gly-Asp is essential for the activity and does not allow any other amino acid combination. Arg and Asp residues might 
promote ionic interactions with the receptor (with the carboxylate of Asp coordinating divalent cations) whereas the Gly imposes steric restrictions. Position 4 
requires a hydrophobic residue in the D-configuration (i.e. D-Phe) for optimal side chain orientation and interaction with the receptor. The amide bond between 
residues 3 and 4 also participates in the binding and therefore may act as a hydrogen bond donor. Finally, position 5 can accommodate a number of residues 
without an impact in the biological activity. 
 
 
 
 
 
Fig. (5). N-methylated cyclic pentapeptides derived from c(RGDfV).  
Table 3.  Biological Activity (IC50) of N-Methylated Cyclic Peptides and Standard Peptides in Inhibiting the Binding of Vn and Fg to Isolated In-
tegrins v3 and IIb3, Respectively 
Peptide IC50 (M) v3 IC50 (M) IIb3 Selectivity  IIb3/v3 
GRGDSPK 0.21    1.7  8.1 
c(RGDfV) 0.0025  1.7    680 
1, c(-N(Me)R-GDfV) 0.0055  5.2  945 
2, c(R-N(Me)G-DfV) 0.045  >  10  n.c. 
3, c(RG-N(Me)D-fV) 0.56  >  10  n.c. 
4, c(RGD-N(Me)f-V) 1.4  >  10  n.c. 
5, c(RGDf-N(Me)V-) 0.00058  0.86 1483 
The selectivity for these receptors is expressed as the ratio between the IC50 values for each integrin subtype [16]. 
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  Regarding the antagonistic activity for v3, the analogues 
with Asp or D-Phe residues N-methylated showed a lower activity 
than the control peptides. Remarkably, peptide 4 is one order of 
magnitude less active compared to the linear peptide. In addition to 
conformational reasons, this behavior could be attributed to the loss 
of a hydrogen bond donor in the peptide bond between Asp and D-
Phe due to N-methylation, since this amide bond was reported to 
contribute to the activity [42]. The modification of the Gly residue 
(e.g. substitution by alanine or -alanine) leads to suppression of 
activity in RGD ligands, therefore the rather high (45 nM) biologi-
cal activity observed for compound 2 was unexpected. From this 
series only analogue 5 displayed an enhanced activity compared to 
c(RGDfV). This peptide, which contains N-methyl Val, had an 
antagonistic affinity of 0.58 nM for v3 and showed only low 
activity for IIb3 (0.86 M) being 1500 times more selective in 
inhibiting the binding of Vn to v3 than Fg to IIb3. Interest-
ingly, it also displayed a relatively high affinity for v5 (in   
the nanomolar range). At this time, the role of this integrin was  
not known, hence a biselective compound was considered of great 
interest. This highly active and selective compound was chosen for 
drug development by Merck and later named Cilengitide.  
  In order to study the effect of N-methylation in the conforma-
tion of the peptide, the three-dimensional structure of Cilengitide 
was determined. Significant structural differences were found. Due 
to steric repulsion the amide bonds between Asp
3-D-Phe
4 and Val
5-
Arg
1 are placed in a more perpendicular orientation regarding the 
plane of the peptide backbone, and two inverse  turns (i) are   
observed with Arg
1 and Asp
3 at the i+1 position. A  turn is also 
observed with Gly
2 in position i+1 (Fig. 6). The i turns compensate 
the hydrogen bond that should be observed in a II’turn, which is 
no longer present. The rotation of the amide bonds Asp
3-D-Phe
4 and 
Val
5-Arg
1 also influences on the orientation of the Asp and Arg side 
chains which move towards a more pseudoequatorial orientation. 
On the contrary, the non-methylated peptide c(RGDfV) places these 
side chains in a pseudoaxial conformation. This finding suggests 
that although a kink in the RGD motif is necessary for v3 activity 
and selectivity towards IIb3, it is not as essential for the binding 
affinity as previously postulated (a distance between Arg and Asp 
C atoms below 0.67 nm) [40]. Remarkably, the conformation   
determined in solution turned out to be identical to the one   
described for Cilengitide bound to the v3 integrin (see section 2.1). 
 
 
 
 
 
 
 
 
 
 
Fig. (6). Three-dimensional structure of Cilengitide obtained by NMR and 
MD calculations. For clarity only the protons from the N-methyl group and 
the amide bonds are shown. The different turns observed are indicated. 
  To summarize this first part, we have described the design and 
synthesis of Cilengitide as a potent and selective integrin ligand. A 
major milestone in the design of this potent compound was the 
introduction of D-amino acids to explore the optimal spatial con-
formation required for biological activity of cyclic RGD-containing 
peptides. Our findings improved drastically the affinity of linear 
RGD peptides for integrin binding, and also established the struc-
tural basis necessary for integrin selectivity. In the next chapter, we 
explore the role of integrins in angiogenesis and cancer, and the 
biochemical background of Cilengitide’s biological activity.  
2. BIOCHEMICAL BACKGROUND 
2.1. Integrins in Angiogenesis and Tumor Vasculature 
  Cell attachment and detachment is crucial for function of all 
higher organisms. Integrins provide controlled adhesion to different 
tissues and signaling into the cell in case of proper adhesion. One  
of the most important processes in embryogenesis, wound healing 
and female menstrual cycle is angiogenesis, since the transport   
of nutrients and oxygen throughout the body to organs and tissues  
is indispensible for the organism [4, 67]. Integrins have distinct 
roles and are critical mediators and regulators in the physiological 
and pathological angiogenesis, including tumor angiogenesis, by 
activating kinases [68]. 
  Integrins are non-covalently associated heterodimers of one  
and one  subunit, altogether forming more than 24 integrins using 
18  and 8  subunits [7]. The  and  subunits are both type-I 
membrane proteins with a large extracellular domain and a   
generally short, non-catalytic cytoplasmic tail, linked by a single 
transmembrane region (Fig. 7) [69]. The physical interaction of 
integrins with ECM proteins promotes cell adhesion and migration, 
and affects signaling pathways that regulate cell proliferation,   
survival, and differentiation as well as cytoskeletal organization and 
force generation [70]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (7). Schematic representation of an integrin in the unligated state. 
  Signaling by integrins can induce or prevent apoptosis as they 
regulate both the expression and activity of pro-apoptotic proteins. 
Additionally, integrins play an important role in the molecular regu-
lation of lymphangiogenesis, which has been recently reviewed in 
the literature [6, 71]. Integrins also contribute to the regulation of 
immunity, inflammation and hemostasis and are involved in many 
pathological conditions such as cancer, autoimmune diseases or 
atherothrombosis [1, 72]. Although numerous in vivo and in vitro 
experiments have shown that integrins expressed on endothelial 
cells play an important role in cell growth, survival and migration 
during angiogenesis [6] and apoptosis, their exact mode of action 
and mechanisms remain unclear [73]. However, many cancer cells 
overexpress certain integrins to control migration, extravasation, 
and homing [70]. 
  The integrins involved in angiogenesis comprise the heterodi-
mers 11, 21, 41, 51, 61, 64, 91, v3, v5 and 
D-Phe4
N(Me)Val5
Arg1 Asp3 γ
γi γi
Gly2
Cytoplasmic
domains
Transmembrane
domains
Extracellular
domains
Ligand-binding
pocket
-propellerCilengitide: The First Anti-Angiogenic Small Molecule Drug Candidate  Anti-Cancer Agents in Medicinal Chemistry, 2010, Vol. 10, No. 10    759 
the glial cell integrin v8 [6]. These receptors are targets of both 
angiogenic activators and inhibitors. Some integrins, such as 51, 
prefer a single ligand (i.e. Fn), whereas other integrins can bind to 
distinct ECM proteins [8]. This is the case for instance of v3 
which binds to Vn, Fn and Fg among others. The combination of 
the integrins expressed on a given cell dictates to what extent the 
cell will adhere to and migrate on different matrices [7]. The bind-
ing of integrins to their natural ligands is in nearly half of the over 
20 known integrins mediated by the RGD recognition motif (see 
section 1.1). RGD-recognizing integrins include 51 and all the 
types of v integrins. 
  Integrin binding to ligands in the ECM induces conformational 
changes in the integrin’s structure and contributes to clustering of 
heterodimers into oligomers [72]. This leads to intracellular signals 
through multiple activation of signaling proteins. This process is 
known as “outside-in signaling” and controls cell polarity, cy-
toskeletal structure, gene expression and cell survival. Integrins are 
bidirectional signaling machines, and they can also respond to in-
tracellular signals, “inside-out signaling”, which regulate the adhe-
siveness to the ECM ligands and thus cell invasion and migration 
[67]. Detached cells undergo apoptosis resulting from a variety of 
events [74]. Thus, the prevention of integrin mediated adhesion to 
the ECM leads to apoptosis and suppression of invasive events like 
liver metastasis and angiogenesis [43]. In addition, detachment of 
cells from the surrounding ECM and appearance of unligated in-
tegrins was demonstrated to trigger the activation of caspase-8 and 
consequently, apoptosis [75-77], a mechanism called “integrin-
mediated death” (IMD) (Fig. 8) [78, 79]. 
  The first crystal structure of the extracellular segment of the 
v3 integrin published in 2001 was a major breakthrough [11]. It 
revealed that the N-terminal segments of both the  and  subunits 
assemble in an ovoid-like head from which two nearly parallel tails 
emerge. The v tail is composed of three -sandwich domains: an 
Ig-like thigh domain and two very similar domains that form the 
calf module. The 3 subunit consists of a plexin-semaphorin-
integrin module which is found in several protein families (plexins, 
semaphorins and integrins), four epidermal growth factor (EGF) 
domains and a -tail domain. The ligand binding site of the RGD 
ligand is located at the interface of the so called -propeller domain 
formed from v and a A domain from 3. 
  In 2002 the crystal structure of the extracellular segment of the 
integrin  v3 complexed with Cilengitide in the presence or ab-
sence of the pro-adhesive cation Mn
2+ was elucidated [12]. The 
structure of Cilengitide and v3 in the presence of Mn
2+ revealed 
that the peptide inserts into a crevice between the -propeller and 
the A domain on the integrin head. Cilengitide forms a slightly 
distorted pentagon (see also Fig. 6) during the interaction, with the 
arginine and the aspartic acid side chains of the RGD motif pointing 
in opposite directions. The guanidinium group of Cilengitide is 
fixed inside a narrow groove (Fig. 9A) formed by the D3-A3 and 
D4-A4 loops of the -propeller by a bidentate salt bridge to Asp
218 
and another salt bridge with Asp
150. The carboxylate group of 
Cilengitide points into a cleft between two loops of the A domain, 
coordinating a Mn
2+ ion at the metal ion-dependent adhesion site 
(MIDAS). It is additionally involved in hydrogen bonds with the 
backbone amides of Tyr
122 and Asn
215. The glycine lies at the inter-
face between the  and  subunits and makes several hydrophobic 
interactions with the integrin surface, including a contact with the 
carbonyl oxygen of Arg
216. As previously mentioned, the conforma-
tion of Cilengitide bound to v3 is almost identical to the confor-
mation of Cilengitide in aqueous solution determined by NMR 
spectroscopy [16]. These findings support our previous observa-
tions, based on ligand-oriented structure-activity studies in the 
process of the development of Cilengitide, and are in agreement 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (8). Schematic representation of integrin activation states and signaling mechanisms. In the bent form the integrin head group points inwards towards the 
cell surface and has low affinity for ligands [80]. During “inside-out signaling” an intracellular activator binds to the -subunit, induces a conformational 
change leading to increased affinity for extracellular ligands [72]. This process is known to regulate cell adhesion, migration and invasion. During “outside-in 
signaling” a ligand binds to the integrin and can induce, because of multivalency, integrin clustering. Activation of a signal cascade leads to intracellular sig-
nals, which regulate cell polarity, survival and migration, changes in cytoskeleton and gene expression. The presence of unligated integrins can activate 
caspase-8, and as a consequence, induce apoptosis in a process known as IMD [78, 79]. 
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with the fact that the RGD sequence is crucial for optimal v3 
binding and that these pharmacophoric groups cannot be replaced. 
The remaining two residues of Cilengitide face away from the  
interface and thus a large fraction of the cyclic peptide has no con-
tact with the v3 integrin surface. 
  A three-dimensional model for the human v5 integrin was 
obtained using homology modeling based on the experimental three 
dimensional structure of v3 in its bound conformation [81]. The 
work assumed that the v and the 5 subunit assemble in a similar 
manner as found for v3 and thus Cilengitide interacts with both 
integrins in a related way (Fig. 9B). The homology model for 51 
was also reported [82]. These models paved the way for the rational 
design of antagonists of these integrins [83]. 
  The publication of the co-crystal structure of Tirofiban associated 
with IIb3 in 2004 elucidated the difference between the binding 
pockets of IIb3 and v3 (Fig. 9C, 9D) [13]. The observation 
that the selectivity for IIb3 and v3 is conferred by the distance 
between the acidic and the basic moiety of the respective ligand 
[41], has now been structurally confirmed. The Asp
224, involved in 
the hydrogen bond with the basic ligand-mimetic side chain, is 
located in the deeper -propeller pocket of IIb, whereas the resi-
dues Asp
150 and Asp
218 of the v-propeller are closer to its shal-
lower pocket. 
2.2. The Role of v3, v5 and 51 in Cancer 
  The repertoire of integrins in endothelial cells of angiogenic 
vessels differs from the integrins expressed in resting endothelial 
cells [84]. Both integrins v3 and v5 are expressed in various 
cell types such as endothelial cells, fibroblasts, epithelial cells, os-
teoblasts, and smooth muscle cells and are upregulated in endothe-
lial cells undergoing angiogenesis. Additionally, they are highly 
upregulated on endothelium during tumor angiogenesis. 
  Tumors with only a small volume of a few cubic millimeters 
may rest for months or years without neovascularization, when the 
balance between pro- and anti-angiogenic signals does not favor the 
growth of the local vasculature [85, 86]. Initiated by local hypoxia, 
tumor cells can switch to the angiogenic phenotype activating the 
expression of vascular endothelial growth factors (VEGFs), which 
can recruit and subsequently activate a family of tyrosine kinase 
receptors [84, 87]. This early event in tumor progression called the 
“angiogenic switch” enables tumors to attract new blood vessels to 
establish a vascular connection with the host and support the 
growth of both, the angiogenic and the non-angiogenic cells [85]. 
Inhibition of VEGF signaling therefore is one of the most promi-
nent targets for anti-angiogenic drugs, as growth factor signaling 
leads to expression of integrins which allow for example tumor 
cells and endothelial cells to migrate to the stimulus [88]. 
  During the invasive phase endothelial cells penetrate the under-
lying basement membrane, proliferate and migrate on the ECM. 
This process enables the cancer cell to pull itself forward into the 
tissue and arranges the endothelial cells into functional vessels [70]. 
In this manner, angiogenesis helps tumor cells to gain access to the 
circulation as well as provides nutrients and oxygen to cancer cells. 
As key components in the interaction between activated, proliferat-
ing endothelial cells and the surrounding stroma, integrins are es-
sential in cancer metastasis and tumor progression. They regulate 
tumor cell survival – by preventing pro-apoptotic signals – and 
malignancy in the ligated and the unligated state [7]. 
  The first evidence for the involvement of specific integrins in 
pathological angiogenesis was found in studies employing antibodies 
and small molecules directed against the v3 integrin [43, 89].   
The v3 and v5 integrins are usually expressed at low levels in 
most adult epithelia but can be highly upregulated in some tumors. 
They are not only highly expressed on morphologically abnormal 
tumor vasculature, but also on tumor cells, including gliomas [6, 
90]. Positron emission tomography (PET) using [
18F]Galacto-RGD 
[91] and validation by immunohistochemistry revealed v3 ex-
pression in different solid tumors of patients but lack of expression 
in normal tissues (e.g. benign lymph nodes, muscles) [92]. It has 
been shown that activation of v3 is required for metastasis in a 
breast cancer carcinoma model [93] and that expression of v3 
and v5 in tumor vasculature correlates with the malignancy of 
neuroblastoma [94, 95]. The selective upregulation of the v3 
receptor in malignant glioma suggests a major role for this integrin 
in this type of cancer. However, it is well documented, that not only 
v3, but also other integrins, such as v5 integrin, are upregu-
lated in this cancer [96, 97].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (9). Cilengitide bound to v3 (A) and to v5 (B) [82]. Binding of 
Tirofiban to IIb3 (C) and of Cilengitide to v3 (D) [13]. Figures C and 
D are obtained, with permission, from Nature Publishing group, Ref 13 
(2004), Macmillan Publishers Ltd. All rights reserved. 
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  Despite the reported important role of v3 in angiogenesis, 
mice lacking the v gene show extensive vasculogenesis and   
angiogenesis [98]. Additionally, mice lacking 3 and 5 integrins 
display enhanced pathological angiogenesis and accelerated tumor 
growth [99]. The dispensable role of v3 in developmental   
angiogenesis is consistent with the finding that humans who carry a 
null mutation in the 3 subunit (Glanzmann thrombasthenia) exhibit 
normal vascular development and angiogenesis [100, 101]. Due to 
the discrepancy between these studies and the observation that v3 
inhibitors suppress angiogenesis, the question of whether the v3 
integrin regulates angiogenesis in a positive or rather negative way 
is still under debate [7, 73, 78, 102]. 
 The  51 integrin and its ligand, Fn, are known to be pro-
angiogenic [103]. Indeed 51 is selectively expressed in angio-
genic vasculature. Similarly to v3 and v5, 51 is also highly 
expressed in endothelium during tumor angiogenesis both in mice 
and in humans, but poorly expressed on normal quiescent blood 
vessels. 51 promotes epithelial cell survival and induces angio-
genesis in vitro, whereas genetic ablation results in embryonic le-
thality with disruption in blood vessel formation [104, 105] and 
blocking antibodies or peptides have shown to inhibit angiogenesis 
in vivo [103]. 
 The  v3, v5 and 51 integrins have partially overlapping 
ligand specifities and 51 might be able to substitute v3 or v5 
biological functions. This could be a reasonable explanation for   
the discrepancy above mentioned [84]. The v3-dependent  
pro-angiogenic pathway is different from that regulated by v5. 
Integrin blocking experiments have shown that VEGF-induced 
angiogenesis is dependent on v5, whereas angiogenesis induced 
by basic fibroblast growth factor (bFGF) expresses v3 [106].   
The expression of the integrin 51 is induced by a variety of   
angiogenic stimuli, such as bFGF and others, but not by VEGF 
[103, 107]. 
2.3. Cilengitide as Integrin Antagonist 
  Due to their primary expression on activated endothelial   
cells, the integrins v3, v5, and 51 are attractive targets for 
cancer therapy [108] and the treatment of non-malignant angiogenic 
disorders [109]. Especially in the case of solid tumors, anti-
angiogenic molecules represent a new potent concept of therapy. 
The inhibition of integrin-ligand interactions suppresses cellular 
growth and induces apoptotic cell death [43, 110, 111]. The vast 
number of reported integrin antagonists comprises monoclonal 
antibodies, peptide and peptidomimetic antagonists and small 
molecules [10, 112]. 
  Therapies directed against angiogenic blood vessels take advan-
tage of the distinct biochemical properties of neovascular vessels 
versus resting vasculature. Currently, several compounds targeting 
integrins are in clinical trials as potential drugs for the treatment of 
numerous diseases including cancer [6]. Among them, Cilengitide 
is the first integrin antagonist in clinical phase III for treatment of 
glioblastoma and in phase II for several other tumors. This drug is 
the only anti-angiogenic small molecule showing subnanomolar 
antagonistic activity for v3 and affinities in the low nanomolar 
range for v5 and 51.  
  Cilengitide acts as a highly potent inhibitor of angiogenesis   
and induces apoptosis of growing endothelial cells via the inhibition 
of the interaction between integrins with their ECM ligands [113, 
114]. Cilengitide was shown to influence cellular adhesion to v3 
ligands, to induce increased apoptosis after detachement of v3 
and v5 expressing cells in vitro [113] and to block the growth of 
human xenografts in nude mice [115]. Additionally, it revealed 
anti-angiogenic and anti-tumor activity in various animal models 
[116-118]. The inhibition of v integrins resulted in significant 
reduction of functional vessel density and retardation of tumor 
growth and metastasis in vivo [117].  
  Recently it has been shown, that v5 mediates metastasis and 
that treatment with Cilengitide of tumor cells which express the 
v5 integrin but not the v3 integrin, effectively prevented me-
tastasis formation [119]. It is documented, that Cilengitide induces 
apoptosis in v expressing tumor cell lines by detaching them from 
Vn and tascin, matrix proteins known to be essential for tumor 
growth and invasion and it also induces apoptosis in both brain 
capillary and brain tumor cells [113]. Additionally, it has been 
documented that treatment with Cilengitide decreases osteolysis of 
breast cancer metastasis in nude rats and the volume of the soft 
tissue tumor components [120]. A study performed in 2009 proved 
that hypoxia stimulates the v3 and v5 integrin pathways 
through focal adhesion kinase (FAK) and that hypoxia activates 
FAK in gioblastoma cell lines [121]. Treatment of glioblastoma 
cells with Cilengitide led to a significant and dose dependent de-
crease of hypoxia-inducible factor 1 (HIF-1 ) intracellular level 
under hypoxic conditions. This study suggests that v3 and v5 
are activated by hypoxia and are key regulators of glioma response 
to hypoxic conditions by controlling HIF-1  degradation. 
  Finally, it has been shown that low nanomolar concentrations of 
Cilengitide paradoxically stimulate tumor growth in vivo by pro-
moting VEGF-mediated angiogenesis [122], an observation that has 
been a matter of debate in the literature [123, 124]. This might be 
the influence of the ligand in the first step of the multistep mecha-
nism to activate integrins and form focal contacts and finally focal 
adhesion [72]. As signal transduction requires dissociation of the 
transmembrane helices and aggregation, blocking the multivalent 
binding at higher Cilengitide concentrations might cause the anti-
angiogenic effect. However, the concentrations used in clinical 
trials largely exceed the described “pro-angiogenic” concentration 
of Cilengitide, and therefore, such a biological effect is not ex-
pected in clinical application [123] (see section 3). 
  As reported, Cilengitide demonstrated anti-angiogenic and anti-
tumor qualities and inhibition of tumor metastasis in many preclini-
cal studies. Additionally, integrin antagonists seem to synergize 
with already established therapeutic treatments, such as radiother-
apy (RT) and chemotherapy [17]. Stabilizing effects in highly vas-
cularized solid tumors by Cilengitide in combination with che-
motherapeutic drugs were demonstrated [117, 125]. Furthermore, 
Cilengitide showed increased efficacy of RT in endothelial cells 
and non-small cell lung cancer (NSCLC) [126]. The combination of 
an integrin antagonist and RT showed a significant delay of tumor 
growth in glioblastoma xenografts compared with either treatment 
individually [127]. Irradiation of tumors reduces the local tumor 
growth, but at the same time upregulates v3 expression [127] and 
enhances local invasion and metastatic spreading [17]. Therefore, it 
is plausible that Cilengitide as an integrin antagonist may normalize 
the tumor vasculature and attenuate some of these radiation-induced 
effects. 
3. CILENGITIDE IN THE CLINICS 
  The above mentioned preclinical studies showed a promising 
synergy between Cilengitide and radio-chemotherapy in order to 
normalize tumor vasculature and attenuate tumor invasion and me-
tastases. In a key preclinical study made by MacDonald and col-
laborators, treatment with Cilengitide showed reduction of brain 
tumor and increased survival on mice with orthotopic brain tumors 
compared to mice treated with an inactive peptide. Interestingly, 
when the tumors were grown in the subcutis of nude mice (hetero-
topic model), no inhibition of tumor growth was observed for the 
mice treated with Cilengitide [116]. These findings suggested that 
brain tumors, which are highly angiogenic, were more susceptible 
to growth inhibition by integrin antagonists and led to subsequent 
clinical investigation. A summary of the most representative   
clinical trials completed of Cilengitide in brain tumors (recently 
reviewed in [17]) and other cancer types can be seen in Table 4.  762    Anti-Cancer Agents in Medicinal Chemistry, 2010, Vol. 10, No. 10  Mas-Moruno et al. 
3.1. Cilengitide as Single Agent for Glioblastoma Treatment 
  The first report of biological activity by an integrin antagonist 
was documented for Cilengitide in a phase I trial in patients with 
recurrent malignant glioblastoma (GBM) (Table 4) [128]. The study 
was undertaken to determine the toxicities and maximum-tolerated 
dose (MTD) of Cilengitide in patients with malignant primary brain 
tumors. In this study Cilengitide showed an unexpected single agent 
(administered without any other drugs) activity for these tumors 
with limited toxicity to doses up to 2,400 mg/m
2. Out of the 51 
patients of the study, five showed objective response (OR): two 
complete response (CR) with improved functional status and no 
tumor recurrence and three partial response (PR). The pharmacoki-
netics (PK) of Cilengitide in this study were comparable to other 
phase I studies in patients with advanced solid tumors, in which it 
was shown that Cilengitide has an apparent terminal half-life of 3 to 
5 h and can be safely administered on a twice per week infusion 
schedule [129, 130]. Interestingly, peak plasma concentrations 
which showed anti-tumor effects in pre-clinical models were ob-
tained at doses  120 mg/m
2 [129]. Another phase I study was con-
ducted in children with refractory brain tumors [131]. Dose limiting 
toxicity (DLT) was not observed but three serious cases of intratu-
moral hemorrhage (ITH) were documented. However, this study 
concluded that a 1,800 mg/m
2 dose of Cilengitide in children   
with brain tumor was devoid of increased risk of ITH. One patient 
had CR and six more had stable disease (SD). These studies were 
promising and encourage pursuing further phase II studies in which 
the most appropriate dose of Cilengitide or the synergy of this   
integrin inhibitor with chemotherapy agents and RT were evaluated 
[132]. A phase II study for patients with recurrent GBM who   
required tumor resection was set to measure a progression-free 
survival rate at 6 months (PFS-6) and examine the delivery of 
Cilengitide into tumor [133]. Treatment with Cilengitide was well 
tolerated and episodes of post-operative hemorrhages were not 
observed. Preliminary data showed significantly increased concen-
trations of the drug in the tumor compared to plasma concentra-
tions, demonstrating a dose-related good delivery of Cilengitide 
into the brain tumor. A multicenter, open-label, randomized phase 
II study was conducted to further evaluate the efficacy and safety of 
Cilengitide among recurrent GBM patients [134]. As previous 
clinical studies showed responses at both the lower and the higher 
dose levels, two Cilengitide dose concentrations were evaluated: an 
intermediate-low (500 mg) dose and an intermediate-high (2000 
Table 4.  Completed Clinical Trials of Cilengitide in Brain Tumors and Other Types of Cancer  
Author/Year  Trial  No. Patients  Purpose   Disease Setting  Cilengitide Dose
a Main  Results  Ref. 
Eskens 
2003 
Phase I  37 patients  Determine safety, 
toxicity and PK 
Metastatic solid 
tumors 
Single agent   
30 to 1600 mg/m
2 
No DLT 
Half-life: 3 to 5 h 
No CR or PR. 3 SD  
[129] 
Friess  
2006 
Phase II  89 patients  Determine safety, PK 
and OS  
Unresectable 
pancreatic cancer 
Cilengitide  
(600 mg/m
2) + Gemcitabine 
No clinical differences compared to 
gemcitabine 
No survival benefit 
[142] 
Hariharan 
2007 
Phase I  20 patients  Determine safety, 
toxicity and PK 
Advanced solid 
tumors 
Single agent 
600 or 1200 mg/m
2 
Well tolerated 
Half-life: 4 h 
No CR or PR., 4 SD  
[130] 
Nabors 
2007 
Phase I  51 patients   Determine MTD 
Evaluate the use of 
perfusion MRI in 
patients with GBM 
Recurrent GBM  Single agent    
120 to 2400 mg/m
2 
No DLT and MTD 
No bleeding 
Tolerated at 2,400 mg/m
2 
2 CR, 3 PR and 16 SD 
[128] 
MacDonald 
2008 
Phase I  31 patients  Determine MTD and 
DLT in children with 
refractory brain tumors 
Pediatric brain 
tumors 
Single agent   
120 to 2400 mg/m
2 
No DLT and MTD 
3 cases of ITH 
1800 mg/m
2 safe dose  
1 CR, 6 SD 
[131] 
Gilbert 
2007 
Phase II  30 GBM 
patients 
Measure a PFS-6  
Examine the delivery of 
Cilengitide into tumor 
GBM requiring 
tumor resection 
Single agent 
3 doses (500 or 2,000 mg) 
before op. After: 2000 mg  
Post-op. hemorrhages not observed 
Cilengitide is efficiently delivered 
into tumor 
[133] 
Reardon 
2008 
 
Phase II  81 GBM 
patients 
Evaluate activity and 
safety in patients with 
GBM at first recurrence 
Recurrent GBM  Single agent 
500 or 2000 mg 
 
Excellent drug safety profile 
Better antitumor activity at 2000 mg 
PFS-6: 15%  
OS: 9.9 months 
[134] 
Nabors 
2009 
Phase II  112 GBM 
patients 
Determine safety  
and OS 
Newly diagnosed 
GBM 
Cilengitide (500 or 2000 mg) + 
TMZ + RT 
Well tolerated therapy 
OS: 18.9 months 
OS at 12 months: 79.5% 
[136] 
Stupp 
2010 
Phase I/IIa  52 GBM 
patients 
Determine safety and 
efficacy of treatment 
Newly diagnosed 
GBM 
Cilengitide  (500 mg) + TMZ + 
RT 
 
PFS-6: 69% 
PFS-12: 33%  
OS: 16.1 months 
OS at 12 months: 68%  
OS at 24 months: 35% 
Longer PFS and OS for patients with 
MGMT promoter methylation 
[137] 
a Cilengitide was administered i.v. twice weekly 
PK pharmacokinetics; DLT dose limiting toxicity; CR complete response; PR partial response; SD stable disease; OS overall survival; MTD maximum-tolerated dose; MRI; magnetic 
resonance imaging; GBM glioblastoma; ITH intratumoral hemorrhage; PFS-n progression-free survival rate at n months; op. operation; TMZ temozolomide; RT radiation therapy; 
MGMT O
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mg) dose, relative to the previous studies. Cilengitide showed an 
excellent safety profile and anti-tumor activity at both concentra-
tions, though showing a more favorable trend for patients treated 
with the higher dose. Radiographic response (RR) (5% vs. 13 %); 
PFS-6 (10% vs. 15%); and median overall survival (OS) (6.5 months 
vs. 9.9 months) were obtained comparing 500 mg vs. 2000 mg, 
respectively. Recently reported follow-up (> 4 years) data showed that 
long-term survival rates were consistently greater with 2000 mg (10.0% 
after 54 months) versus 500 mg (2.4% after 54 months) [135]. 
3.2. Cilengitide in Combination with Radio-Chemotherapy for 
GBM Treatment 
  Preclinical studies demonstrated that Cilengitide in combination 
with chemotherapy agents and in particular with RT and che-
motherapies could have an enhanced anti-tumor activity [127]. 
Furthermore, the low toxicity profile observed for Cilengitide sug-
gested that it could be administered safely in combination with 
cytotoxic therapy. For these reasons, several clinical trials on this 
direction were conducted. A randomized phase II trial combining 
Cilengitide with Temozolomide (TMZ) and RT was reported. The 
objective was to determine safety of this therapy combination and 
OS in 112 patients with newly diagnosed GBM [136]. Combination 
of Cilengitide (500 or 2000 mg) with TMZ and RT was well toler-
ated and showed improved survival (median OS: 18.9 months; OS 
at 12 months 79.5 % of patients). Positive effects for this therapeu-
tic combination were also recently reported for a similar phase I/IIa 
study [137]. Interestingly, the authors of this study showed that 
patients whose tumors had O
6-methylguanine-DNA methyltrans-
ferase (MGMT) promoter methylation, were more susceptible to the 
treatment exhibiting longer PFS and OS. In this sense, methylation 
of MGMT was already described to be a putative marker for benefit 
from TMZ in GBM treatment [138]. On the basis of these results an 
international, randomized, controlled phase III trial (CENTRIC) 
was launched in 2008. This trial was organized by Merck KGaA 
(Germany) in collaboration with the European Organisation for 
Research and Treatment of Cancer (EORTC) and the Canadian 
Brain Tumor Consortium (CBTC) [139]. The study is currently 
recruiting participants, with an estimated enrollment number of 504 
patients. The study completion is estimated on June 2016, with 
primary outcome measures on September 2012 [140]. Only GBM 
patients with MGMT promoter methylation will be considered for 
this study, and Cilengitide will be administered at a unique i.v. high 
dose of 2000 mg twice weekly in combination with TMZ/RT. If 
progression is not observed, Cilengitide treatment will be continued 
for up to 18 months. In parallel, a randomized phase II clinical trial 
has been designed for patients with GBM showing no methylation 
on MGMT gene’s promoter (CORE study) [141], where a recruit-
ment of 264 patients is estimated [140].
 Enrollment of children and 
young adults (6 months to 21 years) with newly diagnosed diffuse 
intrinsic pontine glioma in a phase I study has also recently started 
(CILENT-0902, July 2010) [140]. This study will determine the 
safety and pharmacokinetics of Cilengitide with RT. A summary of 
these, and other studies currently in progress in patients with GBM 
are listed in Table 5. 
Table 5.  Clinical Trials of Cilengitide Currently in Progress  
Trial Estimated  no. 
Patients 
Disease Setting  Purpose/Treatment  Start Date   Estimated Study 
Completion 
Estimated Primary 
Completion 
Ref. 
Phase III 
CENTRIC 
504  Newly diagnosed GBM 
(Methylated gene 
promoter status) 
Evaluate safety and efficacy 
Cilengitide + TMZ+ RT  
September 
2008 
June 2016  September 2012  [139, 140] 
Phase II 
CORE 
264  Newly diagnosed GBM 
(Unmethylated gene 
promoter status) 
Evaluate safety and efficacy  
Cilengitide + TMZ+ RT 
December 
2008 
 ---  December   2012  [140, 141] 
Phase I 
CILENT-0902 
40  Diffuse intrinsic pontine 
glioma 
Evaluate safety and PK 
Cilengitide + RT 
July 2010  July 2015  July 2012  [140] 
Phase II 
ExCentric 
48  Newly diagnosed GBM 
(Unmethylated gene 
promoter status) 
Evaluate safety and efficacy  
Cilengitide + RT+ TMZ + PCB  
November 
2009 
November 2011  January 2014  [140] 
Phase II 
Cecil 
108  Newly diagnosed GBM 
(Unmethylated gene 
promoter status) 
Evaluate safety and efficacy  
Cilengitide or Cetuximab + RT  
+ TMZ 
September 
2009 
--- September  2011  [140] 
Phase I  52  Progressive/recurrent 
GBM 
Evaluate safety and dosage 
Cilengitide + Cediranib maleate 
March 2010  ---  June 2010  [140] 
Phase I/II 
CERTO 
189  Advanced NSCLC  Evaluate safety and efficacy 
Cilengitide + Cetuximab +  
platinum-based chemotherapy 
February 
2009 
November 2011  September 2011  [140, 143] 
Phase I  24  Locally advanced 
NSCLC 
Evaluate MTD  
Cilengitide + Radio/chemotherapy 
March 2010  August 2013  August 2012  [140] 
Phase I/II 
ADVANTAGE 
195 Recurrent/metastatic 
SCCHN 
Evaluate safety and efficacy 
Cilengitide + Cisplatin + 5-FU + 
Cetuximab 
September 
2008 
August 2012  January 2010  [140, 143]  
Phase II 
IRB 2004-697 
106 Metastatic  prostate 
cancer 
Evaluate safety and efficacy 
Cilengitide as single agent 
April 2005  December 2011  October 2007  [140, 144, 145] 
Phase II 
UMCC 2004.045 
IRB 2004-731 
32 Non-metastatic   
prostate cancer 
Evaluate safety and efficacy 
Cilengitide as single agent 
January 2005  December 2016  February 2008  [140, 144] 
Phase I 
CIRAB 
21  Brain metastases from 
lung cancer 
Evaluate DLT and MTD 
Cilengitide + RT 
December 
2008 
December 2011  December 2011  [140] 
GBM glioblastoma; TMZ temozolomide; RT radiation therapy; PK pharmacokinetics; PCB procarbazine; NSCLC non-small cell lung cancer; MTD maximum-tolerated dose; SCCHN 
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3.3. Cilengitide in Other Cancer Types  
  Cilengitide has also been tested for other cancer types different 
than GBM with mixed results. For instance, the use of Cilengitide 
in combination with Gemcitabine in a phase II trial in advanced 
unresectable pancreatic cancer showed no survival benefit com-
pared to treatment with Gemcitabine alone [142]. Currently a num-
ber of phase I and II trials with different cancer types are in pro-
gress (see Table 5) [140]. The CERTO study is a multicenter, open-
label, randomized, controlled phase II study with a safety run-in 
part in patients with advanced NSCLC. This study will evaluate 
both safety and efficacy of Cilengitide treatment in combination 
with Cetuximab, and platinum-based chemotherapy (Cis-
platin/Vinorelbine or Cisplatin/Gemcitabine) [140, 143]. Patients 
with locally advanced NSCLC are also being recruited for a phase I 
study with a combination of RT and chemotherapy (Cisplatin and 
Vinorelbine) with Cilengitide [140]. Cilengitide added to Cisplatin, 
5-fluorouracil (5-FU), and Cetuximab is also being evaluated in an 
open-label, randomized, controlled phase I/II study (ADVAN-
TAGE) in subjects with recurrent and/or metastatic squamous cell 
carcinoma of the head and neck (SCCHN) [140, 143]. Other 
evaluations of Cilengitide in, metastatic or not, prostate cancer 
[140, 144, 145] and brain metastases from lung cancer are also in 
progress (see Table 5). 
CONCLUSIONS 
  The discovery 30 years ago of the RGD motif in Fn was a ma-
jor breakthrough in science. This tripeptide sequence was also iden-
tified in other ECM proteins and was soon described as the most 
prominent recognition motif involved in cell adhesion. Extensive 
research in this direction allowed the description of a number of 
bidirectional proteins, the integrins, which were able to recognize 
and bind to the RGD sequence. Integrins are key players in the 
biological function of most cells and therefore the inhibition of 
RGD-mediated integrin-ECM interactions became an attractive 
target for the scientific community. 
  However, the lack of selectivity of linear RGD peptides repre-
sented a major pitfall which precluded any clinical application of 
RGD-based inhibitors. The control of the molecule’s conformation 
by cyclization and further spatial screening overcame these limita-
tions, showing that it is possible to obtain privileged bioactive 
structures, which enhance the biological activity of linear peptides 
and significantly improve their receptor selectivity. Steric control 
imposed in RGD peptides together with their biological evaluation 
and extensive structural studies yielded the cyclic peptide 
c(RGDfV), the first small selective anti-angiogenic molecule   
described. N-Methylation of this cyclic peptide yielded the much 
potent c(RGDf(NMe)V), nowadays known as Cilengitide. 
  The fact that brain tumors, which are highly angiogenic, are 
more susceptible to the treatment with integrin antagonists, and the 
positive synergy observed for Cilengitide in combination with ra-
dio-chemotherapy in preclinical studies, encouraged subsequent 
clinical trials. Cilengitide is currently in phase III for GBM patients 
and in phase II for other types of cancers, with to date a promising 
therapeutic outcome. In addition, the absence of significant toxicity 
and excellent tolerance of this drug allows its combination with 
classical therapies such as RT or cytotoxic agents. The controlled 
phase III study CENTRIC was launched in 2008, with primary 
outcome measures due on September 2012. The results of this and 
other clinical studies are expected with great hope and interest.  
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